Monoclonal antibodies targeting ERB epitopes are widely used in the treatment of breast cancer (Anti-HER2/neu) and squamous cell carcinoma/colorectal carcinoma (EGFR) and can cause myocardial dysfunction, heart failure, hypertension, and arrythmia [7,9,10]. Here, ERBB2 is linked to squamous cell carcinoma.